XML 23 R13.htm IDEA: XBRL DOCUMENT v3.19.1
Restructuring
3 Months Ended
Mar. 31, 2019
Restructuring and Related Activities [Abstract]  
Restructuring

7. Restructuring

In July 2018, the Company’s Board of Directors approved a restructuring plan to reduce operating costs and better align the Company’s workforce with the needs of its business following the June 27, 2018 announcement that its Phase 3 Leadership 301 clinical trial evaluating once-daily, oral rosiptor for the treatment of IC/BPS failed to meet its primary endpoint. The Company has halted all further development activities with rosiptor.

Under the restructuring plan, the Company reduced its workforce by 30 employees (approximately 53% of total employees) and closed its office in San Bruno, California. Affected employees are eligible to receive severance payments and outplacement services. The Company estimates that it will incur aggregate restructuring charges of approximately $9.4 million related to clinical trial closing costs, contract cancellations, closing of its office in San Bruno, severance payments and other employee-related costs. As of March 31, 2019, $7.3 million of the estimated restructuring charges was paid.

 

The following table shows the total amount expected to be incurred and the liability related to the July 2018 restructuring as at March 31, 2019:

 

     CLINICAL
TRIAL
CLOSING
COSTS
    ONE-TIME
EMPLOYEE
TERMINATION
BENEFITS
    CONTRACT
TERMINATION
COSTS
    SAN BRUNO
OFFICE
CLOSING
COSTS
    TOTAL
EXPENSES
 
(in thousands)                               

Amounts accrued as at January 1, 2018

   $ —       $ —       $ —       $ —       $ —    

Charges for the year

     5,703       1,879       1,108       465       9,155  

Revised estimates during the year

     41       2       187       5       235  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total restructuring costs expected to be incurred

     5,744       1,881       1,295       470       9,390  

Amounts paid during the year

     (2,204 )      (1,881 )      (1,201 )      (470 )      (5,756 ) 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Amounts accrued as at December 31, 2018

     3,540       —         94       —         3,634  

Revised estimates during the period

     13       —         (2 )      —         11  

Amounts paid during the period

     (1,442 )      —         (82 )      —         (1,524 ) 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Amounts accrued as at March 31, 2019

   $ 2,111     $ —       $ 10     $ —       $ 2,121  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

On November 6, 2018, the Company’s Board of Directors approved an additional restructuring plan to further reduce operating costs. Under the restructuring plan, the Company reduced its workforce by 16 employees, including its Chief Operating Officer, Mr. Lloyd Mackenzie, effective December 31, 2018. Further reduction of staff may occur in 2019 pending corporate development activities. Affected employees are eligible to receive severance payments and outplacement services. The Company incurred restructuring charges of $1.0 million in 2018 related to one-timetermination severance payments and other employee-related costs. Substantially all of these charges were paid as at December 31, 2018. Additional restructuring charges of at least $0.7 million are expected to be incurred in 2019.

The following table shows the total amount expected to be incurred and the liability related to the November 2018 restructuring as at March 31, 2019:

 

     ONE-TIME
EMPLOYEE
TERMINATION
BENEFITS
 
(in thousands)       

Total restructuring costs incurred in 2018

   $ 984  

Amount paid in 2018

     (922 ) 
  

 

 

 

Amount accrued at December 31, 2018

     62  

Restructuring costs expected to be incurred in 2019

     658  

Amount paid during the period ended March 31, 2019

     (205 ) 

Amount accrued at March 31, 2019

     (156 ) 
  

 

 

 

Amount expected to be incurred in future periods

   $ 359  
  

 

 

 

Restructuring costs of $0.1 million is recorded in research and development expenses and $0.2 million in general and administrative expenses. The majority of the amounts accrued will be paid by September 30, 2019.